Marken expansion into Latin America continues with Chile, Peru depots

By Zachary Brennan contact

- Last updated on GMT

Marken's expansion in the hot Latin American market continues
Marken's expansion in the hot Latin American market continues

Related tags: Latin america, South america, São paulo

Fresh off the near completion of its depot in Sau Paulo, Brazil, Marken has now also completed the construction of another depot in Santiago, Chile, in order to more easily handle the influx of clinical trial specimens coming from South America.

Chile is now complete, and has been commissioned and we have our license to operate​,” Marken CEO Wes Wheeler told “We’re still hiring a few people there to be fully staffed but we’re all set to go in Santiago​.”

In addition, the company has built another facility in Lima, Peru, inside one of its supplier’s locations “to take advantage of that space – we’ve commissioned, validated it, and we’re in the process of hiring a technical director. My expectation is that by December we’ll be fully operational, we’ll have studies registered there by the end of the year​,” Wheeler said.

And although the depot in Brazil is nearly complete, the company is still waiting on a license to begin operations.

In Sao Paulo we’ve finished the facility, validated it and applied for a license from the local and national licensing boards but getting licenses in Brazil is not the easiest thing in the world so we’re still waiting for the final piece of paper but otherwise we’re done​,” Wheeler said.

The three new depots will mean that Marken will then have five locations in Latin America, with depots in Brazil, Chile, Peru, Argentina and Mexico.

Shift to Lat Am

Wheeler explained that there’s now an “amazing expansion of patients coming out of South America​” as a lot of oncology drug developers are now sourcing patients from Latin America and eastern Europe, Wheeler said. He said he thought about 45% of those patients were recruited by CROs.

He also explained that the company is a specialist in biological samples as “we get most of the samples coming back from South American to central labs in the US. Most of the specimens – the blood samples, cell cultures and tumor cells – are usually coming through Miami and transferred into different US cities. We’re doing a lot of volume, about 15,000 specimens per month. It’s an interesting transition in the volume, which is shifting from what traditionally was Europe and the US to now Latin America and eastern Europe​.”

Asia Moves

In addition to Latin America, Marken is also looking to push further east with a possible new depot in Korea.

We serve all of Asia via Singapore but we had to build something in Beijing because the China market is so special​,” he told us.

The bio revolution is happening and we’re now working now with a few Korean companies because of the influx of biosimilars​,” he said, noting that Marken has an office and a small team now in Korea.

Related news

Show more

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Keys To A Successful Rapid Commercial Launch

Keys To A Successful Rapid Commercial Launch

Catalent Pharma Solutions | 21-Oct-2020 | Insight Guide

Pharma and biotech companies are dedicating resources to new treatments with the hope of helping patients. The quicker they can get products to patients,...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us


View more